Drug interactions
Lisocabtagene maraleucel + Vedolizumab
Severity: Moderate
Lisocabtagene maraleucel and Vedolizumab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lisocabtagene maraleucel is a CD19-directed CAR T-cell product given after lymphodepleting chemotherapy and carries risks of prolonged cytopenia, hypogammaglobulinemia and serious infection. Concurrent vedolizumab may add modestly to infection risk, although its gut-selective action limits systemic effects.
What this interaction means in plain words
Lisocabtagene maraleucel and Vedolizumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Lisocabtagene maraleucel belongs to Oncology; Vedolizumab belongs to Gastrointestinal Tract.
Why it happens
Additive immunomodulation between gut-selective integrin blockade and CAR T-related immune suppression; largely theoretical.
What to do
Reassess whether vedolizumab is needed around lymphodepletion and CAR T infusion and consider holding it until hematologic recovery. Monitor for infection and cytopenias.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lisocabtagene maraleucel and Vedolizumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Vedolizumab
- Natalizumab + Vedolizumab Contraindicated
- Baricitinib + Vedolizumab Major
- Certolizumab pegol + Vedolizumab Major
- Etanercept + Vedolizumab Major
- Golimumab + Vedolizumab Major
- Smallpox vaccine live + Vedolizumab Major
Other interactions of Lisocabtagene maraleucel
Frequently asked questions
Can I take Lisocabtagene maraleucel with Vedolizumab?
MediHelp rates the interaction as moderate. Lisocabtagene maraleucel and Vedolizumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lisocabtagene maraleucel is a CD19-directed CAR T-cell product given after lymphodepleting chemotherapy and carries risks of prolonged cytopenia, hypogammaglobulinemia and serious infection. Concurrent vedolizumab may add modestly to infection risk, although its gut-selective action limits systemic effects.
How serious is the interaction between Lisocabtagene maraleucel and Vedolizumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Reassess whether vedolizumab is needed around lymphodepletion and CAR T infusion and consider holding it until hematologic recovery. Monitor for infection and cytopenias.
What other medicines interact with Vedolizumab?
MediHelp also lists interactions of Vedolizumab with, for example, Natalizumab, Baricitinib, Certolizumab pegol. The full list is on the Vedolizumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
